Alps Group Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALPS Nasdaq 2836 alps-holdings.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alps Group Inc

Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022 - Jun 9th, 2026 6:05 am
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - May 19th, 2026 2:05 pm
Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight - Apr 17th, 2026 6:30 am
Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol - Feb 23rd, 2026 6:00 am
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy - Jan 30th, 2026 6:00 am
Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer - Jan 8th, 2026 6:00 am
Alps Group Inc (NASDAQ:ALPS) CEO Seng Tham's holdings dropped 12% in value as a result of the recent pullback - Dec 12th, 2025 4:24 am
Alps Announces Closing of Business Combination with Globalink Investment Inc. - Oct 31st, 2025 6:00 am